Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATISSE 2: Immunotherapy for Organ Preservation in CSCC
NCT06823479Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2025
- Primary completion
- Feb 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in cutaneous squamous cell carcinoma (cSCC), sponsored by Netherlands Cancer Institute. Primary endpoint: Rate of clinical complete remission after only immunotherapy at 24 months. Started May 2025; status: recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT06823479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06823479.